Response Variability to Drug Testing in Two Models of Chemically Induced Colitis
Authors:
- Roger SuauRSRoger Suau
- Anna GarciaAGAnna Garcia
- Carla BernalCBCarla Bernal
- Mariona LlavesMLMariona Llaves
- Katharina SchieringKSKatharina Schiering
- Eva Jou-OlléEJEva Jou-Ollé
- Alex PertegazAPAlex Pertegaz
- Arce Garcia-JaraquemadaAGArce Garcia-Jaraquemada
- Ramon BartolíRBRamon Bartolí
- Violeta LorénVLVioleta Lorén
- Patri VergaraPVPatri Vergara
- Míriam MañosaMMMíriam Mañosa
Open Access
- 29 March 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6424
Abstract
The lack of knowledge regarding the pathogenesis of IBD is a challenge for the development of more effective and safer therapies. Although in vivo preclinical approaches are critical for drug testing, none of the existing models accurately reproduce human IBD. Factors that influence the intra-individual response to drugs have barely been described. With this in mind, our aim was to compare the anti-inflammatory efficacy of a new molecule (MTADV) to that of corticosteroids in TNBS and DSS-induced colitis mice of both sexes in order to clarify further the response mechanism involved and the variability between sexes. The drugs were administered preventively and therapeutically, and real-time bioluminescence was performed for the in vivo time-course colitis monitoring. Morphometric data were also collected, and colonic cytokines and acute plasma phase proteins were analyzed by qRT-PCR and ELISA, respectively—bioluminescence images correlated with inflammatory markers. In the TNBS model, dexamethasone worked better in females, while MTADV improved inflammation in males. In DSS-colitis, both therapies worked similarly. Based on the molecular profiles, interaction networks were constructed to pinpoint the drivers of therapeutic response that were highly dependent on the sex. In conclusion, our results suggest the importance of considering sex in IBD preclinical drug screening.Keywords
Funding Information
- Spherium Biotech (Barcelona, Spain)
- CIBEREHD (Madrid, Spain)
- Instituto de Salud Carlos III (ISCIII, Government of Spain)
This publication has 73 references indexed in Scilit:
- Comparison of experimental mouse models of inflammatory bowel diseaseInternational Journal of Molecular Medicine, 2013
- Oxidative stress in ulcerative colitis: an old concept but a new concernFree Radical Research, 2012
- Dextran Sodium Sulphate Colitis Mouse Model: Traps and TricksJournal of Biomedicine and Biotechnology, 2012
- Protection of SH-SY5Y Neuronal Cells from Glutamate-Induced Apoptosis by 3,-Disinapoyl Sucrose, a Bioactive Compound Isolated from Radix PolygalaJournal of Biomedicine and Biotechnology, 2012
- Involvement of Interferon-γ in Bowel Disease Pathogenesis by Nitric Oxide Pathway: A Study in Algerian PatientsJournal of Interferon & Cytokine Research, 2010
- Dose-related patterns of glucocorticoid-induced side effectsAnnals of the Rheumatic Diseases, 2009
- T cell transfer model of chronic colitis: concepts, considerations, and tricks of the tradeAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2009
- IL-10 gene therapy prevents TNBS-induced colitisGene Therapy, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Acute-Phase Proteins and Other Systemic Responses to InflammationNew England Journal of Medicine, 1999